Simvastatin

Introduction Overview

Generic Name

simvastatin

Brand Name

Zocor

Dosage Form

oral tablet

Drug Class

HMG CoA reductase inhibitors (Statins)

Pharmacokinetics

Absorption:
Simvastatin is administered orally and is a prodrug that undergoes rapid absorption from the gastrointestinal tract. Peak plasma concentrations of the active hydroxy acid metabolite are reached approximately 1.3 to 2.4 hours after oral dosing. The absolute bioavailability of simvastatin acid is low (about 5%), due primarily to extensive first-pass metabolism in both intestinal wall and liver. Food does not significantly affect the bioavailability of simvastatin, though it is typically recommended to be taken in the evening or with the evening meal to coincide with maximal cholesterol synthesis.

Distribution:
Simvastatin and its active metabolites are highly bound to plasma proteins (about 95%). Following absorption and first-pass metabolism, simvastatin is distributed predominantly to hepatic tissue, the primary site of action. The volume of distribution is relatively small, consistent with its high plasma protein binding and hepatic uptake. Limited penetration into the central nervous system is observed due to poor blood-brain barrier permeation. Its extensive uptake into the liver, primarily via active transport mechanisms, is critical for its pharmacological effects.

Metabolism:
Simvastatin is extensively metabolized by cytochrome P450 3A4 (CYP3A4) isoenzymes in the liver. It is converted from the inactive lactone prodrug to multiple active beta-hydroxy acid metabolites that inhibit HMG-CoA reductase, the enzyme responsible for cholesterol synthesis. Major metabolites include simvastatin hydroxy acid and various hydroxylated forms. This metabolism via CYP3A4 makes simvastatin susceptible to numerous drug-drug interactions with CYP3A4 inhibitors, which can increase plasma concentrations and the risk of toxicity.

Elimination:
Simvastatin and its metabolites are primarily eliminated through biliary excretion into the feces, with less than 13% of the administered dose excreted in urine. The elimination half-life for the active metabolites ranges approximately between 2 and 3 hours after oral administration. The drug does not accumulate significantly with repeated dosing due to this short half-life. Renal impairment has limited impact on simvastatin clearance, but caution is advised due to increased risk of adverse effects in kidney disease. Hepatic impairment may significantly alter pharmacokinetics and increase plasma levels, warranting dosage adjustments or contraindication.

Dosage Forms

Available Dosage Forms:
Simvastatin (Zocor) is available in oral tablet form with multiple strengths to accommodate different therapeutic needs.
- Oral Tablets: 5 mg, 10 mg, 20 mg, 40 mg, and 80 mg strengths.

Dosages for Adults and Adolescents:
For adults, initial dosing typically starts at 10 mg to 20 mg once daily in the evening. The dose may be adjusted based on therapeutic response and LDL cholesterol levels, with common maintenance doses ranging from 20 mg to 40 mg daily. The maximum recommended dose is 80 mg per day, reserved for patients who have been on this dose long-term without muscle adverse effects and under close medical supervision. Adolescents aged 10 years and older with heterozygous familial hypercholesterolemia may start at 10 mg daily, with dose adjustments based on response and tolerance.

Specific Patient Populations:
In patients with renal impairment, no specific dosage adjustment is required; however, increased monitoring for adverse effects is recommended. In hepatic impairment, simvastatin is contraindicated in active liver disease or unexplained persistent elevations of liver enzymes. Elderly patients (>65 years) should be initiated at the lower end of the dose range and monitored closely due to higher susceptibility to muscle toxicity. Patients taking interacting medications (e.g., inhibitors of CYP3A4) should avoid higher doses to minimize risk of rhabdomyolysis.

Mechanism Of Action

Simvastatin is a lipid-lowering agent belonging to the class of HMG-CoA reductase inhibitors, commonly called statins. It acts by competitively inhibiting HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for hepatic cholesterol biosynthesis. This inhibition reduces the conversion of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, a precursor of cholesterol, leading to decreased intracellular cholesterol concentrations.

The reduction in hepatic cholesterol production triggers upregulation of LDL receptors on hepatocyte surfaces, increasing clearance of circulating low-density lipoprotein cholesterol (LDL-C) from plasma. This dual mechanism results in significant lowering of LDL cholesterol levels, moderately reduces triglycerides, and modestly elevates high-density lipoprotein cholesterol (HDL-C). These lipid modifications contribute to decreased atherosclerotic plaque development and cardiovascular risk.

At the cellular level, simvastatin's inhibition of mevalonate synthesis also affects downstream isoprenoid intermediates, which are essential for prenylation of various proteins involved in cell signaling, proliferation, and inflammation. This mechanism may provide additional pleiotropic benefits including improved endothelial function, stabilization of atherosclerotic plaques, reduced oxidative stress, and anti-inflammatory effects, which are independent of lipid-lowering.

Clinical studies have robustly demonstrated that simvastatin reduces major cardiovascular events such as myocardial infarction and stroke, especially in patients with established coronary heart disease or diabetes. Compared with other statins, simvastatin has a well-characterized efficacy and safety profile, but dosing should be carefully managed when combined with other drugs that affect CYP3A4 metabolism to minimize risks of myopathy and rhabdomyolysis.

Pharmacological Actions

Inhibition of HMG-CoA reductase leading to decreased hepatic cholesterol synthesis.
Upregulation of hepatic LDL receptors resulting in increased clearance of LDL cholesterol from plasma.
Reduction of plasma LDL cholesterol and triglycerides, with moderate increase in HDL cholesterol.
Pleiotropic effects including anti-inflammatory and antioxidant actions within vascular endothelium.
Stabilization of atherosclerotic plaques through inhibition of macrophage activity.
Improvement in endothelial function and nitric oxide bioavailability.
Reduction in the synthesis of isoprenoid intermediates affecting cellular signaling pathways.
Decrease in circulating C-reactive protein and other markers of inflammation.
Potential modulation of smooth muscle cell proliferation in the vascular wall.
Reduction of cardiovascular morbidity and mortality in high-risk patient populations.

Therapeutic Or Clinical Uses

Treatment of hypercholesterolemia to lower elevated LDL cholesterol levels.
Management of mixed dyslipidemia including elevated triglycerides.
Primary and secondary prevention of cardiovascular disease including coronary artery disease.
Reduction of risk for myocardial infarction, stroke, and cardiovascular death in patients with established atherosclerosis.
Use in patients with type 2 diabetes to reduce cardiovascular risk.
Management of heterozygous familial hypercholesterolemia in adults and children aged 10 years and older.
Adjunct to diet, exercise, and lifestyle modification in lipid disorders.
Off-label use in some cases for prevention of cardiovascular events in patients with risk factors but normal cholesterol.
Potential adjunctive role in improving endothelial dysfunction.
Part of intensive lipid-lowering therapy protocols post-acute coronary syndrome.

Side Or Adverse Effects

Myopathy, including muscle pain, tenderness, or weakness, potentially progressing to rhabdomyolysis.
Elevations in liver transaminases, indicating possible hepatotoxicity.
Headache, common but generally mild.
Gastrointestinal disturbances such as nausea, constipation, and abdominal pain.
Upper respiratory tract symptoms including stuffy nose, sneezing, and sore throat.
Rare instances of hypersensitivity reactions, including rash and pruritus.
Potential for glucose intolerance and elevated blood sugar levels.
Reports of memory loss or cognitive impairment, though causality is uncertain.
Rare occurrence of kidney damage secondary to severe muscle breakdown.
Allergic reactions including hives and swelling of face or throat.
Dark urine, fatigue, or jaundice indicating possible severe liver injury.
Increased risk of muscle toxicity when combined with certain drugs or in patients with predisposing conditions.
Possible dizziness or blurred vision in some patients.
Occasional reports of peripheral neuropathy.
Rare case reports of interstitial lung disease.

Precautions

Avoid use in patients with active liver disease or unexplained persistent elevations of liver enzymes.
Caution in patients with renal impairment and elderly due to increased risk of muscle toxicity.
Careful monitoring of muscle symptoms and liver function tests during therapy.
Prompt evaluation of any unexplained muscle pain, weakness, or tenderness, especially with systemic symptoms.
Avoidance of grapefruit and grapefruit juice during therapy due to risk of increased simvastatin levels.
Use caution in patients with a history of hypothyroidism or poorly controlled thyroid disease.
Avoid concurrent use with strong CYP3A4 inhibitors or interacting medications that increase risk of rhabdomyolysis.
Monitor blood glucose in diabetic patients as statins may slightly increase blood sugar levels.
Pregnancy and breastfeeding contraindicated; use effective contraception during treatment.
Educate patients to report signs of liver dysfunction including jaundice, fatigue, or dark urine.
Dose adjustment may be necessary in presence of interacting drugs like amiodarone or verapamil.
Discontinue therapy if elevated creatine kinase levels with muscle symptoms occur.
Consider alternative lipid-lowering therapies in patients intolerant to simvastatin.
Implement lifestyle modifications concurrently for optimal lipid control.
Ensure regular follow-up with healthcare provider for laboratory monitoring.

Warnings

Risk of myopathy and rhabdomyolysis which can lead to severe muscle damage and kidney failure.
Contraindicated in pregnancy due to risk of fetal harm and birth defects.
Avoid in patients with active liver disease or elevated hepatic transaminases.
Potential for serious drug interactions leading to elevated simvastatin plasma concentrations.
Risk of increased muscle toxicity in elderly patients and those with renal impairment.
Grapefruit and grapefruit juice can significantly increase risk of toxicity by inhibiting metabolism.
Patients should inform physicians of all concomitant medications to avoid dangerous interactions.
Higher doses (80 mg) carry an increased risk for myopathy; limit use and monitor closely.
Discontinuation is necessary if pregnancy occurs during treatment.
Use with caution in patients consuming more than two alcoholic drinks per day due to hepatic risk.
Rare reports of severe hypersensitivity reactions including skin reactions.
Risk of liver enzyme elevations; periodic liver function testing recommended.
Rhabdomyolysis risk increased when combined with fibrates, niacin, or certain antivirals.
Potential for increased blood sugar levels and new-onset diabetes mellitus.
Patients with thyroid disorders may have increased susceptibility to adverse muscle effects.

Contraindication

Hypersensitivity to simvastatin or any component of the formulation.
Active liver disease, including unexplained persistent elevations of serum transaminases.
Pregnancy and nursing mothers due to potential fetal harm and drug excretion in breast milk.
Concurrent use with certain drugs known to increase risk of myopathy: cyclosporine, danazol, gemfibrozil, nefazodone.
Use with specific antibiotics and antifungals: clarithromycin, erythromycin, telithromycin, itraconazole, ketoconazole, posaconazole, voriconazole.
Concomitant use with hepatitis C protease inhibitors (boceprevir, telaprevir) contraindicated.
Use with HIV protease inhibitors and pharmacokinetic enhancers like ritonavir, cobicistat, and others.
Use in patients with active rhabdomyolysis or history of statin-induced myopathy.
Concurrent use with other lipid-lowering therapies known to increase myopathy risk without medical supervision.
Known hypersensitivity to any statin class medication.

Drug Interactions

CYP3A4 inhibitors such as clarithromycin, erythromycin, ketoconazole, itraconazole increase simvastatin levels.
Hepatitis C medications like boceprevir and telaprevir augment statin exposure leading to increased risk of toxicity.
HIV/AIDS protease inhibitors (atazanavir, ritonavir, darunavir, etc.) and pharmacokinetic enhancers like cobicistat potentiate adverse effects.
Fibrates (gemfibrozil) increase risk of myopathy when combined with simvastatin.
Danazol and cyclosporine are potential inducers of statin muscle toxicity.
Amiodarone, verapamil, diltiazem, and dronedarone may increase simvastatin plasma concentrations.
Ranolazine can raise statin exposure, augmenting the likelihood of musculoskeletal adverse effects.
Fluconazole moderately increases simvastatin systemic levels; monitoring required.
Delavirdine and other agents affecting CYP3A4 enzyme should be used cautiously or avoided.
Green tea consumption may interact with statins affecting their metabolism slightly.
Co-administration with lomitapide requires caution due to pharmacodynamic interactions.
Simvastatin may increase INR when used with warfarin, necessitating closer monitoring.
Drugs that cause liver enzyme elevations may have additive hepatic adverse effects.
Avoid grapefruit and grapefruit juice which can inhibit CYP3A4 mediated metabolism.
Potential interaction with oral contraceptives altering hormone levels.

Preparations Of The Drug

Oral tablets available as simvastatin at strengths of 5 mg, 10 mg, 20 mg, 40 mg, and 80 mg.
Brand name formulations: Zocor tablets with standard oral dosing.
Generic simvastatin products with equivalent bioavailability and FDA approval.
Combination preparation with ezetimibe available under different brand names (not Zocor).
Supplied in bottles with child-resistant caps and detailed dosage instructions.
Formulations designed for oral administration with food or at bedtime.
Packages often include patient information leaflets emphasizing precautions and warnings.
Tablets are standard film-coated and intended for swallowing without breaking.
Storage recommendations include room temperature protection from moisture and heat.
No parenteral or transdermal formulations available commercially.
Preparation for pediatric use adapted based on weight and clinical indication.
Adjusted formulations for patients with swallowing difficulties not commonly available.
Reformulations to improve stability and shelf life provided by manufacturers.
Available as single-agent therapy; no approved liquid oral suspensions.
Pharmaceutical grade manufacturing ensuring consistent potency and safety.